Ambuja Cements Future Growth
Future criteria checks 1/6
Ambuja Cements's revenue is forecast to decline at 8.1% per annum while its annual earnings are expected to grow at 9.8% per year. EPS is expected to grow by 7.9% per annum. Return on equity is forecast to be 7.5% in 3 years.
Key information
9.8%
Earnings growth rate
7.9%
EPS growth rate
Basic Materials earnings growth | 8.3% |
Revenue growth rate | -8.1% |
Future return on equity | 7.5% |
Analyst coverage | Good |
Last updated | 02 Aug 2024 |
Recent future growth updates
Recent updates
Here's Why Ambuja Cements (NSE:AMBUJACEM) Can Manage Its Debt Responsibly
Jul 23Returns On Capital At Ambuja Cements (NSE:AMBUJACEM) Have Stalled
May 30Ambuja Cements' (NSE:AMBUJACEM) Promising Earnings May Rest On Soft Foundations
May 09There's Reason For Concern Over Ambuja Cements Limited's (NSE:AMBUJACEM) Price
Apr 22Ambuja Cements (NSE:AMBUJACEM) Hasn't Managed To Accelerate Its Returns
Feb 01Is Ambuja Cements (NSE:AMBUJACEM) A Risky Investment?
Dec 21Ambuja Cements (NSE:AMBUJACEM) Could Be Struggling To Allocate Capital
Oct 18Is Ambuja Cements (NSE:AMBUJACEM) A Risky Investment?
Sep 22Returns On Capital At Ambuja Cements (NSE:AMBUJACEM) Paint A Concerning Picture
Jul 09Is Ambuja Cements (NSE:AMBUJACEM) Using Too Much Debt?
Jun 18Ambuja Cements (NSE:AMBUJACEM) Will Want To Turn Around Its Return Trends
Mar 26Is Ambuja Cements (NSE:AMBUJACEM) Using Too Much Debt?
Mar 08Weak Statutory Earnings May Not Tell The Whole Story For Ambuja Cements (NSE:AMBUJACEM)
Feb 15Ambuja Cements' (NSE:AMBUJACEM) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 27We Like These Underlying Return On Capital Trends At Ambuja Cements (NSE:AMBUJACEM)
Mar 25Is Ambuja Cements (NSE:AMBUJACEM) Using Too Much Debt?
Mar 08Ambuja Cements' (NSE:AMBUJACEM) Dividend Will Be Increased To ₹6.30
Feb 23Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 266,867 | 42,190 | N/A | N/A | 6 |
3/31/2026 | 230,660 | 33,736 | 5,205 | N/A | 11 |
3/31/2025 | 196,124 | 26,013 | 3,180 | N/A | 12 |
6/30/2024 | 327,582 | 33,175 | N/A | N/A | N/A |
3/31/2024 | 331,596 | 35,768 | 11,634 | 56,458 | N/A |
12/31/2023 | 322,316 | 31,666 | N/A | N/A | N/A |
9/30/2023 | 320,096 | 27,779 | -11,834 | 26,037 | N/A |
6/30/2023 | 317,170 | 20,781 | N/A | N/A | N/A |
3/31/2023 | 310,370 | 19,245 | -27,975 | 5,879 | N/A |
12/31/2022 | 309,828 | 19,385 | -53,902 | -8,362 | N/A |
9/30/2022 | 307,014 | 17,947 | N/A | N/A | N/A |
6/30/2022 | 302,053 | 23,673 | 6,762 | 37,393 | N/A |
3/31/2022 | 291,507 | 24,920 | N/A | N/A | N/A |
12/31/2021 | 289,655 | 27,804 | 29,751 | 53,092 | N/A |
9/30/2021 | 287,931 | 32,220 | N/A | N/A | N/A |
6/30/2021 | 283,154 | 31,780 | 27,037 | 47,608 | N/A |
3/31/2021 | 259,813 | 27,584 | N/A | N/A | N/A |
12/31/2020 | 245,162 | 23,654 | 30,987 | 48,323 | N/A |
9/30/2020 | 241,848 | 22,247 | N/A | N/A | N/A |
6/30/2020 | 240,926 | 19,880 | 36,901 | 53,654 | N/A |
3/31/2020 | 265,225 | 21,538 | N/A | N/A | N/A |
12/31/2019 | 271,036 | 20,950 | 30,713 | 47,387 | N/A |
9/30/2019 | 267,058 | 24,778 | N/A | N/A | N/A |
6/30/2019 | 266,458 | 23,804 | 18,213 | 30,722 | N/A |
3/31/2019 | 264,121 | 22,830 | N/A | N/A | N/A |
12/31/2018 | 260,409 | 21,774 | 5,954 | 17,034 | N/A |
9/30/2018 | 254,518 | 16,121 | N/A | N/A | N/A |
6/30/2018 | 248,200 | 15,850 | N/A | N/A | N/A |
3/31/2018 | 243,478 | 16,147 | N/A | N/A | N/A |
12/31/2017 | 235,855 | 15,164 | N/A | 34,162 | N/A |
9/30/2017 | 224,324 | 13,481 | N/A | N/A | N/A |
6/30/2017 | 215,147 | 12,769 | N/A | N/A | N/A |
3/31/2017 | 206,207 | 12,409 | N/A | N/A | N/A |
12/31/2016 | 201,319 | 11,051 | N/A | 28,103 | N/A |
9/30/2016 | 177,442 | 10,265 | N/A | N/A | N/A |
12/31/2015 | 94,330 | 8,079 | N/A | 15,566 | N/A |
12/31/2014 | 99,606 | 14,865 | N/A | 16,755 | N/A |
12/31/2013 | 91,339 | 12,786 | N/A | 12,675 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMBUJACEM's forecast earnings growth (9.8% per year) is above the savings rate (6.7%).
Earnings vs Market: AMBUJACEM's earnings (9.8% per year) are forecast to grow slower than the Indian market (16.9% per year).
High Growth Earnings: AMBUJACEM's earnings are forecast to grow, but not significantly.
Revenue vs Market: AMBUJACEM's revenue is expected to decline over the next 3 years (-8.1% per year).
High Growth Revenue: AMBUJACEM's revenue is forecast to decline over the next 3 years (-8.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMBUJACEM's Return on Equity is forecast to be low in 3 years time (7.5%).